Co-infections of rickettsiales in clinically healthy, Leishmania infantum seropositive and seronegative dogs: a systematic literature review and new findings from Southern Italy
Parasitology Research · 2025
DOI: 10.1007/s00436-025-08458-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Parasitology Research, 2025. Verfasst von Oana Gusatoaia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, University of Bari, Valenzano, Italy. Hauptthemen laut MEDLINE: Coinfection, Dog Diseases, Leishmaniasis, Visceral, Ehrlichiosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Bari Aldo Moro.
Abstract (Originalsprache)
Canine leishmaniosis (CanL), caused by Leishmania infantum , is a widespread vector-borne disease. In Italy, an endemic region for CanL, overlapping transmission of L. infantum and tick-borne pathogens (TBPs) like Anaplasma phagocytophilum and Ehrlichia canis is increasingly reported. Dogs with clinical leishmaniosis often show higher co-infection rates and pronounced clinicopathological abnormalities. This study presents a systematic literature review and new findings from southern Italy, focusing on co-infections with E. canis and A. phagocytophilum in clinically healthy L. infantum seropositive and seronegative dogs. The systematic review identified two eligible studies. The first reported 34/488 (7%) dogs L. infantum seropositive, with 11.8% also seropositive for A. phagocytophilum . Among 454 seronegative dogs, 3% were seropositive for A. phagocytophilum and 2.4% for E. canis . The second study identified 154/1260 (12.2%) dogs L. infantum seropositive, with co-infection rates of 0.6% and 1.9% for A. phagocytophilum and E. canis , respectively. Among 1106 seronegative dogs, 1.3% were seropositive for A. phagocytophilum and 2.3% for E. canis . In the retrospective study from southern Italy, 90/154 (58.4%) dogs were L. infantum seropositive, with co-infection rates of 4.4% for A. phagocytophilum and 2.2% for A. phagocytophilum and E. canis . Among 64 seronegative dogs, 1.6% showed similar co-infections. This is the first systematic review in Italy, documenting low and comparable co-infection rates with A. phagocytophilum and E. canis in clinically healthy dogs, regardless of L. infantum serostatus. These findings suggest that co-infections may occur independently, offering insights into vector-borne disease dynamics in endemic areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Veterinary Medicine, University of Bari, Valenzano, Italy.
- Department of Veterinary Clinical Sciences, City University of Hong Kong, Hong Kong SAR, China.
- Department of Veterinary Medicine, University of Bari, Valenzano, Italy. andrea.zatelli@uniba.it.
Förderung
- Università degli Studi di Bari Aldo Moro
Zitieren
APA
Gusatoaia, O., Perles, L., Cavalera, M. A., Uva, A., Gernone, F., Otranto, D., & Zatelli, A. (2025). Co-infections of rickettsiales in clinically healthy, Leishmania infantum seropositive and seronegative dogs: a systematic literature review and new findings from Southern Italy. Parasitology Research. https://doi.org/10.1007/s00436-025-08458-4
Vancouver
Gusatoaia O, Perles L, Cavalera MA, Uva A, Gernone F, Otranto D, et al. Co-infections of rickettsiales in clinically healthy, Leishmania infantum seropositive and seronegative dogs: a systematic literature review and new findings from Southern Italy. Parasitology Research. 2025. doi:10.1007/s00436-025-08458-4
BibTeX
@article{Gusatoaia2025,
author = {Gusatoaia, Oana and Perles, Livia and Cavalera, Maria Alfonsa and Uva, Annamaria and Gernone, Floriana and Otranto, Domenico and Zatelli, Andrea},
title = {Co-infections of rickettsiales in clinically healthy, Leishmania infantum seropositive and seronegative dogs: a systematic literature review and new findings from Southern Italy},
journal = {Parasitology Research},
year = {2025},
doi = {10.1007/s00436-025-08458-4}
}
EUVIMED